You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 293 No. 13, April 6, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (2)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Hypertension
 •Alert me on articles by topic

Diuretics Are Color Blind

James D. Neaton, PhD; Lewis H. Kuller, MD

JAMA. 2005;293:1663-1666.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is considered one of the most important recent clinical trials in hypertension. This mega-trial was motivated by (1) the observation that trials of participants with diastolic blood pressure (BP) in the range of 90 to 114 mm Hg did not result in as large a reduction in coronary heart disease (CHD) incidence as the epidemiologic data suggested should be the case; (2) different classes of antihypertensive drugs were thought to have fewer adverse effects (eg, decreased levels of serum potassium, increased levels of blood glucose and blood cholesterol and triglycerides) than diuretics, and these adverse effects might explain the lower than expected effect on CHD of a diuretic-based BP-lowering treatment; and (3) newer agents that had potentially favorable mechanisms of action might provide benefit above and beyond BP control.1-2 The high . . . [Full Text of this Article]

Author Affiliations: Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis (Dr Neaton); and Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pa (Dr Kuller).


RELATED ARTICLE

Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril
Jackson T. Wright, Jr, J. Kay Dunn, Jeffrey A. Cutler, Barry R. Davis, William C. Cushman, Charles E. Ford, L. Julian Haywood, Frans H. H. Leenen, Karen L. Margolis, Vasilios Papademetriou, Jeffrey L. Probstfield, Paul K. Whelton, Gabriel B. Habib, and for the ALLHAT Collaborative Research Group
JAMA. 2005;293(13):1595-1608.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Have ALLHAT, ANBP2, ASCOT-BPLA, and So Forth Improved Our Knowledge About Better Hypertension Care?
Sawicki and McGauran
Hypertension 2006;48:1-7.
FULL TEXT  

Diuretics for Hypertension
Krakoff
Circulation 2005;112:e127-e129.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.